Published in Schmerz on February 01, 2008
Assessing the risk of stroke from neck manipulation: a systematic review. Int J Clin Pract (2012) 1.02
Cerebral infarct presenting with thunderclap headache. J Headache Pain (2009) 0.87
A systematic review of causes of sudden and severe headache (Thunderclap Headache): should lists be evidence based? J Headache Pain (2014) 0.75
Thunderclap headache as the primary clinical feature of a supratentorial embolic cerebral infarct. Neurol Sci (2011) 0.75
A case of cerebellar infarction presenting as thunderclap headache. Neurol Sci (2011) 0.75
Avoiding pitfalls in the diagnosis of subarachnoid hemorrhage. N Engl J Med (2000) 3.16
Thunderclap headache. Lancet Neurol (2006) 2.42
Prospective study of sentinel headache in aneurysmal subarachnoid haemorrhage. Lancet (1994) 1.52
Nimodipine for treatment of primary thunderclap headache. Neurology (2004) 1.18
Thunderclap headache caused by minimally invasive medical procedures: description of 2 cases. Headache (2007) 0.98
Thunderclap headache from complicated sinusitis. Headache (2006) 0.88
Thunderclap headache: an approach to a neurologic emergency. Curr Neurol Neurosci Rep (2007) 0.85
Thunderclap headache as the presenting symptom of myocardial infarction. Headache (2007) 0.82
Persistent primary thunderclap headache responsive to gabapentin. J Headache Pain (2006) 0.81
Thunderclap headache and reversible segmental cerebral vasoconstriction associated with use of oxymetazoline nasal spray. CMAJ (2004) 0.80
Effects of cervical sympathectomy on vasospasm induced by meningeal haemorrhage in rabbits. Arq Neuropsiquiatr (2006) 0.77
Thunderclap headache. Curr Pain Headache Rep (2002) 0.76
Clinical images: Afrin-induced central nervous system vasospasm and thunderclap headache. Arthritis Rheum (2005) 0.76
Adult aqueductal stenosis presenting as a thunderclap headache: a case report. Cephalalgia (2007) 0.76
Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA. N Engl J Med (1999) 3.76
Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology (1995) 1.77
CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. Bone Marrow Transplant (2010) 1.74
Brief report: inherited metabolic myopathy and hemolysis due to a mutation in aldolase A. N Engl J Med (1996) 1.74
[Evaluation of a multimodal pain therapy at the University Pain Centre Dresden]. Schmerz (2009) 1.72
VACTERL with the mitochondrial np 3243 point mutation. Am J Med Genet (1996) 1.72
Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism. Periprocedural safety and mid-term follow-up results of three different device occluder systems. Eur Heart J (2004) 1.69
Validation of the German version of the Brief Pain Inventory. J Pain Symptom Manage (1999) 1.56
Prevalence of smell loss in Parkinson's disease--a multicenter study. Parkinsonism Relat Disord (2009) 1.50
[Use of controlled release opioids in perioperative pain therapy: a standpoint on a new warning advice in the literature on controlled release opioids]. Schmerz (2009) 1.50
[Structure and process quality of multimodal pain therapy. Results of a survey of pain therapy clinics]. Schmerz (2012) 1.41
Atraumatic needle reduces the incidence of post-lumbar puncture syndrome. J Neurol (1994) 1.33
Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain (2011) 1.28
Biochemical and ultrastructural changes of skeletal muscle mitochondria after chronic electrical stimulation in rabbits. Pflugers Arch (1985) 1.23
Olfactory function in idiopathic Parkinson's disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J Neural Transm (Vienna) (2002) 1.21
Exercise-induced fibre type transitions with regard to myosin, parvalbumin, and sarcoplasmic reticulum in muscles of the rat. Pflugers Arch (1984) 1.17
[Recommendations of the updated LONTS guidelines. Long-term opioid therapy for chronic noncancer pain]. Schmerz (2015) 1.16
Neuronal differentiation and long-term culture of the human neuroblastoma line SH-SY5Y. J Neural Transm Suppl (2007) 1.13
Assessment and treatment of neuropathic cancer pain following WHO guidelines. Pain (1999) 1.12
Transfection of mitochondria: strategy towards a gene therapy of mitochondrial DNA diseases. Nucleic Acids Res (1995) 1.11
Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett (1994) 1.10
Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. Palliat Med (2000) 1.06
Parkinson's disease and depression: evidence for an alteration of the basal limbic system detected by transcranial sonography. J Neurol Neurosurg Psychiatry (1997) 1.05
Olfactory function in Parkinsonian syndromes. J Clin Neurosci (2002) 1.04
[MIDOS--validation of a minimal documentation system for palliative medicine]. Schmerz (2000) 1.04
Neurological disability, psychological distress, and health-related quality of life in MS patients within the first three years after diagnosis. Mult Scler (2009) 1.03
Assessing cognition and psychomotor function under long-term treatment with controlled release oxycodone in non-cancer pain patients. Acta Anaesthesiol Scand (2006) 1.01
[Multimodal pain therapy: An established procedure?]. Schmerz (2012) 1.01
Ipsi- and contralateral fibre transformations by cross-reinnervation. A principle of symmetry. Pflugers Arch (1983) 1.01
Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients. Palliat Med (2001) 1.01
Pathophysiology of the MELAS 3243 transition mutation. J Biol Chem (1997) 1.00
[Chronic non-cancer-related pain. Long-term treatment with rapid-release and short-acting opioids in the context of misuse and dependency]. Schmerz (2013) 1.00
Olfactory function in patients with idiopathic Parkinson's disease: effects of deep brain stimulation in the subthalamic nucleus. J Neural Transm (Vienna) (2004) 0.98
Inter- and intraspecies comparisons of fibre type distribution and of succinate dehydrogenase activity in type I, IIA and IIB fibres of mammalian diaphragms. Histochemistry (1984) 0.98
Cognitive impairment and its influence on pain and symptom assessment in a palliative care unit: development of a Minimal Documentation System. Palliat Med (2000) 0.98
High-dose tramadol in comparison to low-dose morphine for cancer pain relief. J Pain Symptom Manage (1999) 0.97
Variable penetrance of a familial progressive necrotising encephalopathy due to a novel tRNA(Ile) homoplasmic mutation in the mitochondrial genome. J Med Genet (2004) 0.97
A comparison of two ATPase based schemes for histochemical muscle fibre typing in various mammals. Histochemistry (1982) 0.96
[Efficacy of opioid analgesia at the superior cervical ganglion in neuropathic head and facial pain]. Schmerz (2006) 0.95
The prognosis of mild cognitive impairment in the elderly. J Neural Transm Suppl (1998) 0.95
Perspectives on recent advances in the understanding and treatment of Parkinson's disease. Eur J Neurol (2009) 0.95
[Measuring pressure pain thresholds. Comparison of an electromechanically controlled algometer with established methods]. Schmerz (2007) 0.95
[Attitudes towards patient care at the end of life. A survey of directors of neurological departments]. Nervenarzt (2004) 0.94
Clinical spectrum of the MELAS mutation in a large pedigree. Acta Neurol Scand (1995) 0.93
[Deficits in the treatment of chronic pain. 2. Possibilities for improvement through the Pain Therapy Ambulant Network (STAN)]. Z Arztl Fortbild Qualitatssich (2000) 0.92
New insights into the metabolic consequences of large-scale mtDNA deletions: a quantitative analysis of biochemical, morphological, and genetic findings in human skeletal muscle. J Neuropathol Exp Neurol (2000) 0.91
Levels and proteolytic processing of chromogranin A and B and secretogranin II in cerebrospinal fluid in neurological diseases. J Neural Transm (Vienna) (1998) 0.91
Kinetic tremor in Parkinson's disease--an underrated symptom. J Neural Transm (Vienna) (2006) 0.91
Olfactory bulb volumes in patients with idiopathic Parkinson's disease a pilot study. J Neural Transm (Vienna) (2005) 0.90
A mild juvenile variant of type IV glycogenosis. Brain Dev (1992) 0.90
Baroreflex sensitivity and power spectral analysis in different extrapyramidal syndromes. J Neural Transm (Vienna) (2008) 0.90
HLA typing and Parkinson's disease. Eur Neurol (2003) 0.90
Cricopharyngeal achalasia is a common cause of dysphagia in patients with mtDNA deletions. Neurology (2001) 0.89
Cerebral vasculitis with multiple infarcts caused by lyme disease. Cerebrovasc Dis (2003) 0.89
Neurological multisystem manifestation in multiple symmetric lipomatosis: a clinical and electrophysiological study. Muscle Nerve (1995) 0.89
Oxidative stress to dopaminergic neurons as models of Parkinson's disease. Ann N Y Acad Sci (2004) 0.89
[Adherence to neurologic treatment. Lessons from multiple sclerosis]. Nervenarzt (2008) 0.89
Relationships between early alterations in parvalbumins, sarcoplasmic reticulum and metabolic enzymes in chronically stimulated fast twitch muscle. Pflugers Arch (1983) 0.88
DNA typing for natural killer cell inhibiting HLA-Cw groups NK1 and NK2 by PCR-SSP. J Immunol Methods (1998) 0.88
Chronic alcohol consumption and cerebral indices of oxidative stress: is there a link? Alcohol Clin Exp Res (2001) 0.88
Mutation analysis in myophosphorylase deficiency (McArdle's disease). Ann Neurol (1998) 0.88
[Multiple sclerosis management system 3D. Moving from documentation towards management of patients]. Nervenarzt (2012) 0.88
[Physicians' knowledge and attitudes concerning the use of opioids in the treatment of chronic cancer and non-cancer pain]. Schmerz (2010) 0.88
A method for quantitative extraction of enzymes and metabolites from tissue samples in the milligram range. J Histochem Cytochem (1982) 0.87
Metabolic patterns in malignant gliomas. J Neurooncol (1995) 0.87
Fibre type specific transformations in the enzyme activity pattern of rat vastus lateralis muscle by prolonged endurance training. Pflugers Arch (1983) 0.87
Rotigotine transdermal system for perioperative administration. J Neural Transm (Vienna) (2006) 0.87
Modafinil for excessive daytime sleepiness in myotonic dystrophy. Neurology (2001) 0.87
Treatment of Parkinson's disease in the advanced stage. J Neural Transm (Vienna) (2013) 0.86
Chronic progressive external ophthalmoplegia is associated with a novel mutation in the mitochondrial tRNA(Asn) gene. Biochem Biophys Res Commun (1994) 0.86
Immunohistochemical, volumetric, and functional neuroimaging studies in patients with idiopathic Parkinson's disease. J Neurol Sci (2009) 0.85
Depression and care-dependency in Parkinson's disease: results from a nationwide study of 1449 outpatients. Parkinsonism Relat Disord (2011) 0.85
[Differential therapeutic aspects of analgesia with oral sustained-release strong opioids: application intervals, metabolism and immunosuppression]. Schmerz (2008) 0.85
Effects of low frequency electrical stimulation on enzyme and isozyme patterns of dystrophic mouse muscle. FEBS Lett (1981) 0.85
Focal myositis of the temporal muscle. Muscle Nerve (1993) 0.85
[Morphine dose and side effects: a comparison of older and younger patients with tumor pain]. Dtsch Med Wochenschr (2000) 0.85
The TaClo concept: 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo), a new toxin for dopaminergic neurons. J Neural Transm Suppl (1995) 0.84
[Chronic pain patients' readiness to change after multimodal treatment. Short- and long-term effects]. Schmerz (2012) 0.84
Circadian cortisol, depressive symptoms and neurological impairment in early multiple sclerosis. Psychoneuroendocrinology (2011) 0.84
Pneumonia and in-hospital mortality in the context of neurogenic oropharyngeal dysphagia (NOD) in stroke and a new NOD step-wise concept. J Neurol (2010) 0.84
Cranial MRI and CT in patients with left atrial myxoma. Neuroradiology (1992) 0.84
Regional sublocalization of the human CD69 gene to chromosome bands 12p12.3-p13.2, the predicted region of the human natural killer cell gene complex. Eur J Immunol (1993) 0.84
[Dysphagia diagnostics and therapy of acute stroke: federal survey of certified stroke units]. Nervenarzt (2012) 0.84
Differentiation of parkinsonian syndromes according to differences in executive functions. J Neural Transm (Vienna) (2003) 0.84
Hypertrophic cardiomyopathy with mitochondrial myopathy. A new phenotype of complex II defect. Jpn Heart J (1993) 0.83
The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: evolution in the tradition of the DAL/GPOH studies. Klin Padiatr (2004) 0.83
Metabolic changes in patients with mitochondrial myopathies and effects of coenzyme Q10 therapy. J Neurol (1998) 0.83
Contrast-enhanced transcranial color-coded duplexsonography in stroke patients with limited bone windows. AJNR Am J Neuroradiol (2000) 0.83
Valsalva manoeuvre in patients with different Parkinsonian disorders. J Neural Transm (Vienna) (2009) 0.83
Rapid reduction in parvalbumin concentration during chronic stimulation of rabbit fast twitch muscle. FEBS Lett (1983) 0.83
[Switching opioids to transdermal fentanyl in a clinical setting]. Schmerz (1999) 0.82
Adult-onset glycogen storage disease type II: phenotypic and allelic heterogeneity in German patients. Neurogenetics (1998) 0.82
Pergolide protects dopaminergic neurons in primary culture under stress conditions. J Neural Transm (Vienna) (2002) 0.82
Mitochondrial DNA mutations in multiple symmetric lipomatosis. Mol Cell Biochem (1997) 0.82
Age-specific cerebral perfusion in 4- to 15-year-old children: a high-resolution brain SPET study using 99mTc-ECD. Eur J Nucl Med (1997) 0.82
A comparative microphotometric study of succinate dehydrogenase activity levels in type I, IIA and IIB fibres of mammalian and human muscles. Histochemistry (1982) 0.82
[Deficits in the treatment of chronic pain (I)]. Z Arztl Fortbild Qualitatssich (2000) 0.82
Becker muscular dystrophy: detection of unusual disease courses by combined approach to dystrophin analysis. Muscle Nerve (1992) 0.81
Multisystem triglyceride storage disorder without ichthyosis in two siblings. Acta Paediatr (1994) 0.81